{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 44,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a decision tree/process flow to map patient cohorts to clinical outcomes and subsequent trial progression.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/14",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.75,
        "x": 0.02,
        "y": 0.21
      },
      "kind": "diagram",
      "text": "Flowchart showing BA3011 Monotherapy and Combination cohorts branching into specific sarcoma subtypes, then mapping to interim results and advancement decisions.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbac77af-f50c-41ae-a90d-5dc15d47618b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.78,
        "y": 0.36
      },
      "kind": "paragraph",
      "text": "Interim results satisfied pre-defined 'Go' criteria into part 2 of the Phase 2 BA3011 study in multiple sarcoma subtypes: UPS - clear guidance from FDA, enrolling phase 2, part 2 as initial indication; Osteosarcoma, liposarcoma and synovial - pursue registration post UPS approval",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d932e868-624b-418b-9b92-6380c5deec33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.11,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Pre-defined criteria for each subgroup up to 10 patients: 'No Go' if 0 CR/PR and PFS rate at 3 months <40%; 'Go' if ≥1 CR/PR or PFS rate at 3 months ≥40%. * enrollment as of Feb 28, 2022; Cohorts in gray continuing enrollment until sufficient sample size is achieved. **Included in UPS cohort. BA3011 dose 1.8 mg/kg Q2W. PFS, progression-free survival; PR, partial response; UPS, undifferentiated pleomorphic sarcoma.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a19e8aa8-99bc-4d0b-86a1-88423aa44632",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 2, part 1 topline interim analysis results confirm Phase 1 signal following BA3011 in refractory sarcoma subtypes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea91559e-d4d0-4185-8e0e-56d7f6a91b1b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "407f12d1-4bb5-458c-980b-d2e368a6043a",
      "evidence": "Flowchart showing BA3011 Monotherapy and Combination cohorts branching into specific sarcoma subtypes, then mapping to interim results and advancement decisions.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "f86dabca-60d5-422e-bbd3-d95f3474efb7",
      "evidence": "The slide maps clinical trial cohorts through a decision-making process based on interim results.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "e244782d-5a81-420e-819d-b97c530d994b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "slides 10-16 provide market sizing information",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 21,
      "from": 11,
      "beatId": "9dc7924a-cf61-4c29-9fd6-e666a2b3daec",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "slides 11-21 provide traction information",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e3b4bfda-4f05-4903-9455-c38c0aa043e5",
      "evidence": "slides 11-21 provide data on the effectiveness of CABs",
      "position": 0,
      "objective": "To highlight the potential benefits of CABs in cancer therapy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}